Stocks · News reference
Silexion Therapeutics shares are trading lower after the company announced additional preclinical findings from its ongoing translational immuno-oncology program evaluating SIL204 in human KRAS-mutant cancer cells.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Silexion Therapeutics Q2 EPS $(5.17) Misses $(2.12) Estimate
Silexion Therapeutics (NASDAQ:SLXN) reported quarterly losses of $(5.17) per share which missed the analyst consensus estimate of $(2.12) by 143.87 percent. This is a 88.03 percent increase over losses of $(43.20) per
Nasdaq Surges 150 Points; US Inflation Rate Slows To 3.4% In July
US stocks rise, Nasdaq up 150 points. Dow up 0.13%, Nasdaq up 0.62%, S&P 500 up 0.35%. IT shares up 1.2%, healthcare down 0.9%. CPI rises 3.4%.
Silexion Therapeutics shares are trading lower after the company announced the pricing of its $2.5 million public offering of 3,846,161 shares at $0.65 per share.